VEGFA and macular retinal edema: Over the last decade, antibody-based biopharmaceutical compounds designed to target vascular endothelial growth factor (VEGF) have revolutionized treatment and prognosis for several retinal diseases, including wet age-related macular degeneration1,2, diabetic macular edema3 and macular edema secondary to retinal vein occlusion4.